Abstract:Klisyri (KX01) is a dual tubulin/Src protein inhibitor that has shown potential therapeutic effects in several tumor models. However, a phase II clinical trial in patients with bone-metastatic castration-resistant prostate cancer was halted because of lack of efficacy. We previously reported that KX01 binds to the colchicine site of β-tubulin and its morpholine group lies close to α-tubulin's surface. Thus, we hypothesized that enhancing the interaction of KX01 with α-tubulin could increase tubulin inhibition and synthesized a series of KX01 derivatives directed by docking studies. Among these derivatives, 8a exhibited more than 10-fold antiproliferation activity in several tumor cells than KX01 and significantly improved in vivo antitumor effects. The X-ray crystal structure suggested that 8a both bound to the colchicine site and extended into the interior of α-tubulin to form potent interactions, presenting a novel binding mode. A potential clinical candidate for cancer therapy was identified in this study.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01961?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01961</a>.Characterization of key compounds, antiproliferation activity data, MTD, table of protein crystal data collection and refinement statistics, and HPLC purity traces for key final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_001.pdf">PDF</a>)Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_002.csv">CSV</a>)Structural data for compounds 6a, 6d, and 6r (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_003.pdb">PDB</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_004.pdb">PDB</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_005.pdb">PDB</a>)This article has not yet been cited by other publications.

Molecular simulation study on shikonin derivatives as potent Bcl-xl inhibitors

Design, Synthesis, And Interaction Study Of Quinazoline-2(1h)-Thione Derivatives As Novel Potential Bcl-X(L) Inhibitors

[Antitumor effect research progress of shikonin and its derivatives]

Design, synthesis and mechanism of novel shikonin derivatives as potent anticancer agents

Design,synthesis and in vitro activity study of a novel Bcl-2 protein inhibitors

Design and Synthesis of Fluoroacylshikonin As an Anticancer Agent.

Synthesis and Biological Evaluation of Novel Shikonin Ester Derivatives As Potential Anti-Cancer Agents

Study of inhibitors based on the key sites of Bcl-2 protein

Shikonin and Its Derivatives: a Patent Review

Design, Synthesis and Biological Evaluation of Cinnamic Acyl Shikonin Derivatives

Semi-synthesis and anti-tumor activity of 5,8-O-dimethyl acylshikonin derivatives.

Synthesis and Biological Evaluation of Heterocyclic Carboxylic Acyl Shikonin Derivatives

Design, synthesis, and biological evaluation of shikonin and alkannin derivatives as potential anticancer agents via a prodrug approach.

Synthesis, biological function and evaluation of Shikonin in cancer therapy

De novo design, synthesis and evaluation of benzylpiperazine derivatives as highly selective binders of Mcl-1.

Synthesis and Antitumour Activity of Β-Hydroxyisovalerylshikonin Analogues.

Design, synthesis and biological evaluation of benzoylacrylic acid shikonin ester derivatives as irreversible dual inhibitors of tubulin and EGFR.

Synthesis of Aryl Dihydrothiazol Acyl Shikonin Ester Derivatives As Anticancer Agents Through Microtubule Stabilization.

Design, Synthesis, and Bioactivity Evaluation of Dual-Target Inhibitors of Tubulin and Src Kinase Guided by Crystal Structure

Novel Shikonin Derivatives Targeting Tubulin As Anticancer Agents.

Design, Synthesis and Biological Evaluation of Shikonin Thio-Glycoside Derivatives: New Anti-Tubulin Agents